Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.

Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D.

Prim Care Diabetes. 2010 Jul;4(2):113-7. doi: 10.1016/j.pcd.2010.04.001. Epub 2010 May 4.

PMID:
20444662
[PubMed - indexed for MEDLINE]
2.

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).

Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M.

Diabetes Obes Metab. 2011 Jan;13(1):81-8. doi: 10.1111/j.1463-1326.2010.01323.x.

PMID:
21114607
[PubMed - indexed for MEDLINE]
3.

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

Davies MJ, Chubb BD, Smith IC, Valentine WJ.

Diabet Med. 2012 Mar;29(3):313-20. doi: 10.1111/j.1464-5491.2011.03429.x.

PMID:
21883438
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.

Lee WC, Conner C, Hammer M.

Clin Ther. 2010 Sep;32(10):1756-67. doi: 10.1016/j.clinthera.2010.08.010.

PMID:
21194600
[PubMed - indexed for MEDLINE]
5.

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.

Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR.

Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Review.

PMID:
22985213
[PubMed - indexed for MEDLINE]
6.

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.

Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R.

Diabet Med. 2011 Mar;28(3):333-7. doi: 10.1111/j.1464-5491.2010.03074.x.

PMID:
21309842
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group.

Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.

PMID:
18931095
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group.

Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x.

PMID:
20590735
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ; LEAD-2 and LEAD-3 Study Groups.

Diabetes Obes Metab. 2009 Dec;11(12):1163-72. doi: 10.1111/j.1463-1326.2009.01158.x.

PMID:
19930006
[PubMed - indexed for MEDLINE]
10.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
[PubMed - indexed for MEDLINE]
11.

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group.

Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x.

PMID:
21205128
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Liraglutide: from clinical trials to clinical practice.

Gough SC.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:33-40. doi: 10.1111/j.1463-1326.2012.01576.x. Review.

PMID:
22405267
[PubMed - indexed for MEDLINE]
13.

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.

Pharmacotherapy. 2009 Nov;29(11):1280-8.

PMID:
19873688
[PubMed - indexed for MEDLINE]
14.

Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.

González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, Wacher-Rodarte N, Martínez-Abundis E, Aguilar-Salinas C, Islas-Andrade S, Arechavaleta-Granell R, González-Canudas J, Rodríguez-Morán M, Zavala-Suárez E, Ramos-Zavala MG, Metha R, Revilla-Monsalve C, Beltrán-Jaramillo TJ.

J Diabetes Complications. 2009 Nov-Dec;23(6):376-9. doi: 10.1016/j.jdiacomp.2008.09.002. Epub 2008 Oct 11.

PMID:
18849173
[PubMed - indexed for MEDLINE]
15.

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.

Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB.

Diabet Med. 2011 Jun;28(6):715-23. doi: 10.1111/j.1464-5491.2011.03276.x.

PMID:
21388442
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.

Gao L, Zhao FL, Li SC.

Int J Technol Assess Health Care. 2012 Oct;28(4):436-44. doi: 10.1017/S0266462312000608. Epub 2012 Sep 24.

PMID:
23006540
[PubMed - indexed for MEDLINE]
17.

The efficacy and safety of liraglutide.

Jeong KH, Yoo BK.

Int J Clin Pharm. 2011 Oct;33(5):740-9. doi: 10.1007/s11096-011-9552-8. Epub 2011 Sep 28. Review.

PMID:
21952951
[PubMed - indexed for MEDLINE]
18.

[Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].

González-Ortiz M, Martínez-Abundis E; Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones.

Rev Invest Clin. 2004 May-Jun;56(3):327-33. Spanish.

PMID:
15612515
[PubMed - indexed for MEDLINE]
19.

Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.

Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:16-24. doi: 10.1111/j.1463-1326.2008.00883.x.

PMID:
18435670
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk